MedTrace Logo

An Exploratory Study of High-dose Glivec in Patients With CML-CP Using Molecular Endpoints

NCT01216085 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2021-03-10

No results posted yet for this study

Summary

This study is locally amended study from CSTI571K2301 to evaluate the efficacy and safety of high-dose Glivec in Korean patients group with chronic phase of CML. Molecular response at 60 months after Glivec administration will be described.

Conditions

  • CML
  • Imatinib

Interventions

DRUG

high-dose imatinib

Study patients will receive 400 mg twice daily oral administration in the morning and the evening.

Sponsors & Collaborators

Principal Investigators

  • Dong-Wook Kim, MD, PhD · Catholic Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2011-07-31
Completion
2011-07-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01216085 on ClinicalTrials.gov